S. El Kazzouli, N. El Brahmi, S. Mignani, M. Bousmina, M. Zablocka and J. -P. Majoral Pages 4995 - 5010 ( 16 )
Metallodrugs (organometallic complexes) bearing at least one metal-carbon bond - represent original and powerful tools for diverse therapeutic applications based on the development of “bioorganometallic chemistry”. To date, various metallodrugs were described with very interesting biological activities as antimalarials, antibacterials, neuroprotectors, against arthritis, for chemotherapy etc. Anticancer Pt-based drugs are the main complexes used in the treatment of several cancers, but unfortunately these complexes show elicit and severe toxicities and resistance effects. The remarkably unique and tunable properties of dendrimers have made them promising tools for diverse biomedical applications such as diagnostics, gene therapy and drug delivery including in oncology. Recent studies have shown that well designed dendritic carriers overcome such as poor solubility, permeability, biocompatibility, bioavailability and toxicity of the native drug. This review reports on the recent advances for the use of metallodrugs and dendritic based carriers (drug-dendrimer conjugates and drug encapsulation) in oncology. Advantages, limitations and opportunities in oncology of such materials are discussed and compared.
Metal complexes, dendrimers, drugs, nanotheraphy, oncology
INANOTECH, (Institute of Nanomaterials and Nanotechnology), MAScIR (Moroccan Advanced Science, Innovation and Research Foundation), ENSET, Av. Armee Royale, Rabat, Morocco.